Health Economics›NK- and T-cell lymphoma›Untreated

Untreated

NK- and T-cell lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
SMILE Variant #01 Partial	—	R 11 718	21d	—	—	~6	~R 70 309 indirect	—
DDGP Variant #01 Partial	—	R 4 367	21d	—	—	6	R 26 199 PFS proxy	2

2 of 2 regimens shown